Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ULTRAWIDEFIELD INDOCYANINE GREEN ANGIOGRAPHIC CHANGES AFTER PHOTODYNAMIC THERAPY IN CENTRAL SEROUS CHORIORETINOPATHY: Certain Study Report 3.

Retina (Philadelphia, Pa.)·2025
Same author

[Imaging and classification of central serous chorioretinopathy-What do I really need?]

Die Ophthalmologie·2025
Same author

Choroidal hyperpermeability patterns correlate with disease severity in central serous chorioretinopathy: CERTAIN study report 2.

Acta ophthalmologica·2024
Same author

METHYLATION-ASSOCIATED PATHWAYS IN MACULAR TELANGIECTASIA TYPE 2 AND OPHTHALMOLOGIC FINDINGS IN PATIENTS WITH GENETIC METHYLATION DISORDERS.

Retina (Philadelphia, Pa.)·2024
Same author

SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Retina (Philadelphia, Pa.)·2023
Same author

Clinical characteristics of gyrate atrophy compared with a gyrate atrophy-like retinal phenotype.

European journal of ophthalmology·2023

Related Experiment Video

Updated: Aug 7, 2025

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

3.1K

[Photodynamic therapy in Germany-Quo vadis?]

L Pauleikhoff1, K Rothaus2, F Groß-Bölting2

  • 1Klinik für Augenheilkunde, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland.

Die Ophthalmologie
|March 8, 2023
PubMed
Summary

Photodynamic therapy (PDT) use in Germany has declined due to shifts in treatment for conditions like age-related macular degeneration. Current data suggests a potential underprovision of PDT for central serous chorioretinopathy (CSC).

Keywords:
Central serous chorioretinopathyChoroidal haemangiomaMyopic choroidal neovascularisationNeovascular age-related macular degenerationPolypoidal choroidal vasculopathy

More Related Videos

An In Vitro Approach to Photodynamic Therapy
04:53

An In Vitro Approach to Photodynamic Therapy

Published on: August 17, 2018

8.8K
LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation
05:13

LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation

Published on: January 24, 2025

419

Related Experiment Videos

Last Updated: Aug 7, 2025

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

3.1K
An In Vitro Approach to Photodynamic Therapy
04:53

An In Vitro Approach to Photodynamic Therapy

Published on: August 17, 2018

8.8K
LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation
05:13

LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation

Published on: January 24, 2025

419

Area of Science:

  • Ophthalmology
  • Medical Therapy

Context:

  • Photodynamic therapy (PDT) was initially approved for neovascular age-related macular degeneration (nAMD) and myopia-related choroidal neovascularization (mCNV).
  • Off-label uses include choroidal hemangioma, polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy (CSC).

Purpose:

  • To analyze the trends in PDT treatment volumes in Germany from 2006 to 2021.
  • To examine the changing spectrum of indications for PDT.

Summary:

  • PDT treatments in Germany decreased significantly from 1072 in 2006 to 202 in 2019.
  • The primary indications shifted from nAMD and mCNV to CSC and choroidal hemangiomas.
  • An estimated 1330 PDTs are needed annually for chronic CSC alone, indicating a potential shortfall.

Impact:

  • The decline in PDT is attributed to the rise of intravitreal injections for nAMD and mCNV.
  • PDT is the recommended treatment for chronic CSC, yet current provision appears insufficient.
  • Addressing PDT underprovision requires reliable verteporfin supply, streamlined insurance approvals, and enhanced collaboration between practitioners.